Illumina (NASDAQ:ILMN) Given New $225.00 Price Target at Stifel Nicolaus

01 Aug 2026, 09:18 by Danessa Lincoln · The Markets Daily

Illumina (NASDAQ:ILMN – Free Report) had its target price increased by Stifel Nicolaus from $155.00 to $225.00 in a report published on Friday morning,Benzinga reports. They currently have a buy rating on the life sciences company’s stock.

A number of other research firms also recently weighed in on ILMN. Leerink Partners raised their price target on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. JPMorgan Chase & Co. upgraded Illumina from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $125.00 to $185.00 in a research note on Wednesday, June 10th. Citigroup increased their price objective on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. Piper Sandler raised their target price on shares of Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 1st. Finally, Evercore reissued an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Nine analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Illumina has an average rating of “Hold” and a consensus price target of $175.47.

Check Out Our Latest Research Report on Illumina

Illumina Trading Up 0.0%

Illumina stock opened at $205.10 on Friday. The firm has a 50-day moving average of $176.70 and a 200-day moving average of $147.24. Illumina has a one year low of $88.00 and a one year high of $205.93. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The company has a market cap of $31.03 billion, a price-to-earnings ratio of 38.26, a P/E/G ratio of 3.03 and a beta of 1.47.

Illumina (NASDAQ:ILMN – Get Free Report) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 30.54% and a net margin of 18.36%.The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the previous year, the business earned $1.19 earnings per share. Illumina’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts expect that Illumina will post 5.22 earnings per share for the current fiscal year.

Insider Activity

In other Illumina news, SVP Patricia Leckman sold 783 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the transaction, the senior vice president owned 21,259 shares of the company’s stock, valued at $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the sale, the senior vice president owned 15,056 shares in the company, valued at $2,093,386.24. This represents a 4.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. 2.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Illumina

A number of large investors have recently added to or reduced their stakes in the business. WCM Investment Management LLC lifted its holdings in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Illumina by 97.0% in the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after purchasing an additional 1,352,731 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after purchasing an additional 1,028,099 shares during the last quarter. Morgan Stanley raised its position in shares of Illumina by 66.0% in the fourth quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock valued at $331,710,000 after purchasing an additional 1,005,474 shares during the period. Finally, Vaughan Nelson Investment Management L.P. bought a new position in shares of Illumina in the first quarter valued at about $106,462,000. Institutional investors own 89.42% of the company’s stock.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Q2 results exceeded expectations: Illumina reported $1.16 billion in revenue, up approximately 9.4%–9.5% year over year, while non-GAAP diluted EPS of $1.31 topped the $1.23 consensus estimate. Clinical demand and NovaSeq X placements were key growth drivers. Illumina Q2 financial results
Positive Sentiment: Full-year guidance was raised: Management increased fiscal 2026 non-GAAP EPS guidance to $5.30–$5.40 and revenue guidance to approximately $4.60–$4.64 billion, modestly ahead of analyst expectations. Illumina outlook
Positive Sentiment: Analysts raised price targets: JPMorgan lifted its target to $230 and maintained an “overweight” rating; Stifel raised its target to $225 and assigned a “buy” rating. TD Cowen increased its target to $210 but retained a “hold” rating. These revisions signal greater confidence in Illumina’s earnings outlook, although targets vary considerably.
Positive Sentiment: AI and drug-discovery opportunities remain a catalyst: CEO Jacob Thaysen highlighted genomic medicine and artificial intelligence applications in life sciences. Eli Lilly also joined Illumina’s Billion Cell Atlas alliance, which aims to create large-scale genomic datasets for identifying disease mechanisms and drug targets. Eli Lilly joins Billion Cell Atlas
Neutral Sentiment: Investors are taking profits near record levels: With ILMN trading close to its one-year high, the strong results may have prompted a “sell-the-news” response as investors sought evidence of further upside beyond the guidance increase.
Negative Sentiment: China and margins remain concerns: Greater China revenue declined 12%, while full-year non-GAAP operating-margin guidance remained unchanged at 23.4%–23.6%. Management also expects NovaSeq X instrument-placement growth to moderate year over year in the second half. Illumina China and margin analysis
Negative Sentiment: Insider selling may add pressure: Reported insider activity over the past six months included 41 sales and one purchase, though such transactions may reflect scheduled or personal portfolio activity rather than a direct view of fundamentals.

About Illumina

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.